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Fibromyalgia (FM) is a syndrome involving diffuse body pain with asso-ciations of fatigue, sleep disturbance, cognitive changes, mood dis-
turbance and other variable somatic symptoms (1). FM is a common pain 
disorder estimated to affect 2% to 4 % of the population, of whom 80% 
are women (2); it is most prevalent in the third to fifth decade of life.
Pain is the primary complaint in patients with FM. Fatigue is the 
most common associated complaint and is present in >90% of patients 
(1). Sleep abnormalities result in changes in sleep latency, sleep disturb-
ance and fragmented sleep, leading to impaired daytime function (3,4). 
Mood disorders, including depression and anxiety, are present in up to 
three-quarters of patients with FM (5). Due to the nature of FM, many 
patients experience problems with their activities of daily living (ADL) 
and poor quality of life, and may end up on disability, which has a signifi-
cant impact on them and their families. In the United States, the cost 
for service utilization in an individual FM patient was >$2000 in 1997, 
with reports in the order of $4000 per year per patient for Canada and 
Europe (6-9). There is currently no cure for FM. Ideal management 
includes both nonpharmacological and pharmacological treatments 
using a multimodal approach, with active patient participation fostered 
by a strong patient-centred locus of control (10).
Abnormalities in pain processing have been identified at various 
levels in the peripheral, central and sympathetic nervous systems, 
as well as the hypothalamo-pituitary-adrenal axis stress-response 
system. Documented abnormalities include evidence of peripheral 
sensitization and wind-up phenomenon, central sensitization with 
changes in functional magnetic resonance imaging and single-photon 
emission computed tomography scans of the brain, increased levels of 
substance P in the cerebrospinal fluid and impairment of descending 
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BAckgRouNd: The search for effective treatments for fibromyalgia 
(FM) has continued for years. The present study premises that thalamocor-
tical dysrhythmia is implicated in fibromyalgia and that low-frequency 
sound stimulation (LFSS) can play a regulatory function by driving neural 
rhythmic oscillatory activity.
oBjecTive: To assess the effect of LFSS on FM. 
MeTHod: The present open-label study with no control group used a 
repeated-measures design with no noncompleters. Nineteen female volun-
teers (median age 51 years; median duration of FM 5.76 years) were adminis-
tered 10 treatments (twice per week for five weeks). Treatments involved 
23 min of LFSS at 40 Hz, delivered using transducers in a supine position. 
Measures (repeated before and after treatment) included the Fibromyalgia 
Impact Questionnaire, Jenkins Sleep Scale, Pain Disability Index, sitting and 
standing without pain (in minutes), cervical muscle range of motion and 
muscle tone. Mean percentages were calculated on end of treatment self-
reports of improvement on pain, mood, insomnia and activities of daily living. 
ResuLTs: Significant improvements were observed with median scores: 
Fibromyalgia Impact Questionnaire, 81% (P<0.0001); Jenkins Sleep Scale, 
90% (P<0.0001); and Pain Disability Index, 49.1% (P<0.0001). 
Medication dose was reduced in 73.68% of patients and completely discon-
tinued in 26.32%. Time sitting and standing without pain increased sig-
nificantly (P<0.0001). Cervical muscle range of motion increased from 
25% to 75% (P=0.001), while muscle tone changed from hypertonic to 
normal (P=0.0002). 
coNcLusioN: In the present study, the LFSS treatment showed no 
adverse effects and patients receiving the LFSS treatment showed statisti-
cally and clinically relevant improvement. Further phase 2 and 3 trials are 
warranted. 
key Words: 40 Hz; Fibromyalgia; Low frequency; Music medicine; Neural 
circuit dysrhythmia; Rhythmic sensory stimulation
L’effet de la stimulation sonore à basse 
fréquence chez les patients atteints de 
fibromyalgie : une étude clinique
HisToRiQue : La recherche de traitements efficaces contre la fibromyal-
gie (FM) se poursuit depuis des années. Selon la prémisse de la présente 
étude, la dysrythmie thalamocorticale contribue à la FM et la stimulation 
sonore à basse fréquence (SSBF) peut avoir une fonction régulatrice en 
stimulant l’activité rythmique oscillatoire neuronale.
oBjecTiF : Évaluer l’effet de la SSBF sur la FM.
MÉTHodoLogie : La présente étude ouverte sans groupe témoin a fait 
appel à des mesures répétées que tous ont terminées. Dix-neuf volontaires 
de sexe féminin (âge médian de 51 ans; durée médiane de FM de 5,76 ans) 
se sont fait administrer dix traitements (deux fois par semaine pendant cinq 
semaines). Ces traitements consistaient en une SSBF de 40 Hz pendant 
23 minutes, transmise par transducteurs aux patientes en décubitus dorsal. 
Les mesures (répétées avant et après le traitement) incluaient le question-
naire sur les effets de la fibromyalgie, l’échelle de sommeil de Jenkins, 
l’indice d’incapacité causée par la douleur, la période de position assise et 
debout sans ressentir de douleur (en minutes), l’amplitude de mouvement 
des muscles cervicaux et le tonus musculaire. Les pourcentages moyens 
étaient calculés d’après les autodéclarations d’atténuation de la douleur, de 
l’humeur, de l’insomnie et des activités de la vie quotidienne à la fin du 
traitement.
RÉsuLTATs : Les chercheurs ont observé des améliorations consi-
dérables aux indices médians : questionnaire sur les effets de la fibromyal-
gie, 81 % (P<0,0001); échelle de sommeil de Jenkins, 90 % (P<0,0001), et 
indice d’incapacité de la douleur, 49,1 % (P<0,0001). La dose du médica-
ment était réduite chez 73,68 % des patientes et complètement abandon-
née chez 26,32 % d’entre elles. La période en position assise et debout sans 
ressentir de douleur augmentait considérablement (P<0,0001). L’amplitude 
de mouvement des muscles cervicaux passait de 25 % à 75 % (P=0,001), 
tandis que le tonus musculaire passait d’hypertonique à normal (P=0,0002).
coNcLusioN : Dans la présente étude, le traitement par SSBF ne pro-
voquait pas de réactions indésirables, et les patientes qui le recevaient 
présentaient une amélioration pertinente sur le plan statistique et clinique. 
Des essais de phase 2 et de phase 3 s’imposent.
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noxious inhibitory control (11,12). Some forms of chronic pain appear 
to alter thalamocortical connections, causing a disruption of thalamic 
feedback and the possibility that chronic pain may be related to thal-
amocortical dysrhythmia (TCD) (13). There is increasing evidence for 
altered thalamic function in pain patients with chronic pain (14,15) 
and FM (16-18). Previous literature suggests that lowered thalamic 
function in FM patients represents a ceiling effect of descending pain 
inhibition (16) maintained by the persistent excitatory input of pain 
signals. Support for this mechanism was found in a study in which 
normalization of reduced thalamic activity was observed in response 
to analgesic treatment (nerve blockade) in patients with peripheral 
neuropathic pain (19). In TCD, normal thalamocortical resonance 
is disrupted by changes in the behaviour of neurons in the thalamus.
Music and pain
Pain theory and music: Although there have been numerous studies 
investigating music and pain (20), few have been adequately theorized in 
relation to dominant pain theories to explain why music reduces pain. 
This may be due, in part, to the inadequacy of early pain theories, such as 
the discredited specificity theory, intensity theory and pattern theory (21), 
and to weaknesses in the gate control theory (GCT), which has been 
been proposed as the basis for some music effects. Although GCT (22) 
postulated that affective and cognitive responses, such as music-responsive 
attention and psychological states, influenced the gate through efferent 
descending fibres, research has shown that GCT oversimplified neural 
systems (21). Melzack (23) proposed a more adequate pain theory that 
explains the effects of music as a unified brain mechanism-based body-self 
neuromatrix (NM). Sensory, cognitive and affective dimensions are fully 
credited with affecting pain perception, and these dimensions are subject 
to cognitive-evaluative (attention, expectation, anxiety, valence) and 
motivational-affective (neurotransmitter, hormonal, limbic) inputs. 
Although exact mechanisms are not yet understood, NM offers an 
explanation as to why functions of music, such as distraction, stress and 
anxiety reduction, and aesthetic pleasure, reduce pain perception. 
Although GCT was superseded by NM to explain typical music functions, 
GCT does explain why stimulation of touch fibres can reduce pain per-
ception, as has been demonstrated with certain applications of low-
frequency sound stimulation (LFSS), which induces mechanical 
vibrotactile stimulation of mechanoreceptors and spinal cord functioning, 
not unlike electrical skin and spinal cord stimulation (24). However, nei-
ther the GCT nor NM allow explanation of experiential phenomena, 
including pain, associated with rhythmic oscillatory coherence (25,26) 
and how music as rhythmic vibration can drive oscillatory coherence. The 
correlation of thalamocortical oscillatory dysrhythmia with pain has been 
demonstrated (27,28) but no definitive theory has been established 
cognitive and affective effects of music: Given the role that neuro-
transmitters, hormones and the limbic system play in pain according to 
the NM theory, it is highly relevant that music has been shown to affect 
the release of endorphins (29-37), dopamine (38,39) and serotonin 
(40,41), and decrease cortisol levels (39,42-47). A recent review (45) of 
400 published scientific articles investigating music as medicine found 
strong evidence that music has effects on brain chemistry, has mental 
and physical health benefits on management of mood and stress reduc-
tion, and that it is the rhythmic stimulation of music, rather than the 
melody, that has the greatest antipain effect in the brain. 
gcT and sensory effect of sound: GCT suggests that stimulating the 
touch senses in the nerve origin region of pain will serve to ‘close the 
gate’ to the transmission of pain. LFSS, variously known as vibroacous-
tic or physioacoustic therapy, stimulates the mechanoreceptors in the 
body and cellular structures more deeply, thereby potentially serving to 
block pain transmission. LFSS, usually delivered through chairs or 
beds specially fitted with low frequency transducers, has been found to 
improve mobility (48), increase circulation (49), decrease low-density 
lipoprotein levels and blood pressure (50), help decrease pain (49,50), 
and reduce muscle strain and stiffness (49). 
Studies involving LFSS have examined specific pain conditions: 
rheumatoid arthritis using 40 Hz (51); polyarthritis in hands and chest 
using 40 Hz (52,53); low back pain using 52 Hz (52,53); knee replace-
ment pain (54); postoperative gynecological pain (55); menstrual pain 
and dysmenorrhea using 52 Hz (52,53); and sports injuries (52,53,56).
Music and FM: The effect of music on pain though sensory, cognitive 
and affective dimensions has been demonstrated. The effect of LFSS on 
various pains conditions has also been demonstrated. Little research has 
specifically focused on the effects of music or LFSS on FM. Chesky et al 
(57) studied the immediate effects of music and musically fluctuating 
vibration (60 Hz to 300 Hz) on tender point pain in patients with FM. 
According to the results, musically fluctuating vibration failed to alter 
pain perception in FM. Onieva-Zafra et al (58) studied the effect of four 
weeks of daily music listening to unspecified ‘classical’ music mixed with 
salsa music. The music listening group showed significant reductions in 
pain, measured using the McGill Pain Scale (sensory [P=0.04] and 
evaluative [P=0.02]). The control group received no treatment and 
showed no significant change. Müller-Busch and Hoffmann (59) studied 
chronic pain patients, including patients with FM, with a treatment of 
active music therapy using unspecified performed music. Results found 
significant reduction in reported pain intensity but no change in depres-
sion and anxiety scores. Leão and da Silva (60) found that women with 
chronic pain experienced less pain (P=0.001) after listening to classical 
music. The few studies of sound and FM that exist primarily draw on 
cognitive and affective effects of music. LFSS and FM research has not 
previously been theorized and conducted as in the present study.
Tcd as a basis for chronic pain
TCD is an abnormal condition of the oscillatory network between the 
thalamus and cortex characterized by an increase in resonant low-fre-
quency oscillations in the theta range, with attendant ‘dark’ areas of 
reduced 40 Hz coherent oscillation in the cortex. TCD disrupts nor-
mal intrabrain connectivity and results in disturbed sensation, cogni-
tion, affect and motor performance (27,61-63). One of the conditions 
known to be associated with TCD is chronic pain (63-67). Specifically, 
reduced connectivity between the thalamus and the orbitofrontal 
cortex has been observed in FM patients (68). Although there is not 
complete scientific agreement on the basis of FM, the present study is 
based on the assumption that it is at least partially neurogenic and that 
TCD is, therefore, implicated. 
Rhythmic sensory stimulation 
Music essentially consists of vibration at multiple frequencies. When fre-
quencies are beyond 16 Hz, they are heard as pitches, but each individual 
sound wave can be considered to be a separate stimulative event. 
Consequently, a pitch of 40 Hz, heard as a low pitch close to the lowest ‘E’ 
on the piano, is not a singular stimulation, but rather exerts 40 stimuli per 
second. When this stimulus is applied to the ears as sound waves it ‘drives’ 
a brain response through the auditory system. The same effect can be 
obtained with an isochronous sound created with amplitude modulation 
(69). When the 40 Hz sound is processed by transducers installed in a 
chair, the effect is felt as vibrotactile and can ‘drive’ a response through 
the somatosensory system. The effect can also be created and brain 
response observed with mechanical vibration (70-72). Rhythmic sensory 
stimulation (RSS) similarly extends to the visual domain (73-75).
TCD as a malfunction of coherent rhythmic oscillation should be 
subject to ‘stabilization’ through rhythmic driving of oscillatory neural 
activity. Llinás and Ribary (76) showed a reset of the thalamocortical 
oscillation with auditory stimulation. Ross et al (70) showed an effect 
of 40 Hz steady-state oscillation with vibratory stimulus. Theoretically, 
the effect of RSS to regulate the TCD related to neurogenic pain is the 
foundational premise of the present study.
The present study speculates that TCD is implicated in FM and 
that RSS can play a rehabilitative role through driving neural rhyth-
mic oscillatory activity, and resetting or regulating the dysrhythmia. 
However, RSS, when applied as full body vibrotactile stimulation, as 
in the present study, may also contribute to a reduction in FM symp-
toms by blocking pain perception through GCT, or by improving 
lymphatic drainage and lowering vascular congestion (77).
Effect of sound stimulation on fibromyalgia
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MeTHods
Participants
Following Research Ethics Board approval from Wilfrid Laurier 
University (Waterloo, Ontario), a total of 19 female volunteer subjects, 
with a median age of 51 years and median duration of FM of 5.76 years, 
were recruited for the present study. At recruitment, patients’ FM diag-
nostic criteria assessment (78) was 15 (median) with a minimum of 
eight and maximum of 19. Information regarding study design, treat-
ments, contraindications and theoretical basis for the therapy was given 
to each participant. Informed consent was obtained from the partici-
pants. Table 1 shows the characteristics of the participants.
intervention
The treatment consisted of two sessions per week for five weeks, for a 
total of 10 treatments. At each session, patients received 23 min of LFSS 
at a 40 Hz frequency (79), delivered with the SL5 lounge from Nexneuro 
(USA). The power level of the sound was the same for all subjects (deci-
bel level not measured). They were not specifically instructed to do 
anything other than lie back and relax. Participants experienced a mild 
vibrotactile sensation on their body as well as a low-level hum. No 
patient reported any discomfort or annoyance. Blood pressure and pulse 
rate were checked and documented in every session before and after the 
treatment while patients were on the lounge. 
instrumentation – assessment and outcome measures
initial assessment: An initial assessment was conducted by a medical 
doctor consisting of a complete physical examination addressing the 
history of previous therapies, most offending symptom, and medica-
tions and dosage used. Subjects were asked to give a subjective rating 
of pain, mood, insomnia and ADL. The same medical doctor then 
examined the participants’ ability to sit and stand without pain (meas-
ured as length of time in minutes) based on participant self-report, 
referenced to tasks such as watching television or washing dishes. No 
standardized scale was used. Each subject was then examined separ-
ately by a doctor of chiropractic medicine to determine range of 
motion (ROM) and muscle tone in different areas of their body. Each 
subject then completed the Fibromyalgia Impact Questionnaire (FIQ) 
(80), the Jenkins Sleep Scale (JSS) (81) and the Pain Disability Index 
(PDI) (82,83). This comprehensive pretreatment assessment was per-
formed as an indicator of steady baseline condition on which to make 
treatment effect comparisons.
Although not part of the standard diagnostic criteria for FM, 
physical dysfunction is associated with the constellation of signs and 
symptoms of FM patients. ROM was included in the present study to 
identify whether functional improvements were achieved with 
vibroaccoustic therapy. Other studies have used ROM measurements 
to quantify similar improvements of physical function when per-
forming different forms of therapies (84,85). Similarly, muscle tone 
was examined as an outcome based on an extensive literature describ-
ing how pathophysiology can be expressed as pain, increased muscle 
tone and tension (86-88). One study by Kokebie et al (89) quantified 
this presentation using a pressure gauge. Furthermore, there are several 
studies that have used this sign as an indicator for condition improve-
ment, albeit through other forms of therapeutic techniques (90,91).
outcome assessment: Immediately after the 10th LFSS treatment ses-
sion, each participant was assessed on the 12 measures used in the 
initial assessment. 
second outcome assessment: Precisely two weeks after their 10th 
LFSS session, during which they received no LFSS treatment, subjects 
were further assessed regarding when symptoms reoccurred (in days), 
with a retrospective self-report related to pain and sleep and, of the 
standardized measures, only the PDI. The JSS was not reassessed 
because its standardized follow-up interval is one month. 
Analysis
The present study used a repeated measures design. There were no 
noncompleters. The Wilcoxon signed rank test (WSR) was used com-
pare initial and final values on FIQ, JSS, PDI, length of ability to sit 
and stand without pain (in minutes), ROM and cervical muscle tone. 
Mean percentages were calculated on self reports of improvement on 
pain, mood, insomnia and ADL 
ResuLTs ANd discussioN
Highly significant results were found in the present study; thus, caution 
needs to be taken in interpretation and we urge follow-up research with 
a blinded controlled trial. Pain is a highly subjective experience and dif-
ficult to measure objectively. The impact of pain is more amenable to 
measurement; therefore, three measures of the impact of pain were used: 
the FIQ, JSS and PDI. Table 2 presents the before-treatment (score 
88.8) to after-treatment (score 16.8) reduction in pain impact (81%) 
measured using the FIQ, which was statistically significant (P<0.0001; 
WSR). A comparable impact was measured using the PDI (Table 3) 
with a 49% before-after treatment reduction (P<0.0001; WSR). Sleep is 
TablE 1
Demographic and medical characteristics at recruitment
Range
Minimum Maximum
Age, years, median (q1, q3) 51 (46, 56) 38 65
Sex, n (%)
   Female 19 (100)
   Male 0 (0)
FM diagnostic criteria 
assessment, median (q1, q3)
15 (10, 19) 8 19
Duration of FM, years, mean ± SD 5±2.9 0.16 16
Main FM symptom Pain (100%)
FM Fibromyalgia; q Quartile
Figure 1) Fibromyalgia Impact Questionnaire (FIQ) before and after 
comparison
TablE 2
Fibromyalgia Impact Questionnaire (FIQ) and Jenkins 
Sleep Scale (JSS) results
Test Median Mean ± SD
Range Signed 
rank PMinimum Maximum
FIQ initial 88.8 85.8±10.9 47.0 94.9
FIQ final 16.8 19.9±13.8 3.3 55.5
Difference 72 65.9 95 <0.0001
JSS initial 20 19.16±2.36 10 20
JSS final 2 4.11±4.21 0 16
Difference 18 15.05 95 <0.0001
TablE 3
Pain Disability Index reduction
Minimum Maximum Mean ± SD P
Reduction in Pain 
Disability Index score
11.0 44.0 26.89±9.67 <0.0001
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strongly affected by FM, with some studies reporting 90% of patients 
having disturbed sleep (92,93). The before-treatment JSS median score 
of 20 was reduced after treatment to 2, an improvement of 90% 
(P<0.0001; WSR) (Table 1). Figures 1 and 2 graphically illustrate the 
changes in FIQ and JSS. Although the after-treatment scores are signifi-
cantly different than before treatment, there is less uniformity in the 
‘after’ scores, as indicated by the greater scatter in Figures 1 and 2 and by 
the higher SDs in Table 1. 
A highly important indicator of the impact of FM is the number of 
days patients miss work. This single scale from the FIQ indicated that 
the median days of missed work before treatment was four days per 
week, which was reduced to one day per week after the treatment 
(P<0.0001 WSR). 
A strong indicator of pain experienced is the amount of medica-
tion used. Table 4 shows that after treatment, 73.68% of patients 
reported using a reduced dose of medication and 26.32% of patients 
had completely discontinued use of pain medicine.
Table 4 shows patients’ subjective self-report of the degree of 
improvement during the course of treatment on pain, mood, insomnia 
and ADL. Median scores were are improved by >65%. Subjective 
assessment of pain and ADL are >70% in median. Patients were asked 
for a global impression of change in their condition following treat-
ment. Slightly less than 90% reported their condition to be much or 
very much better, with none reporting it being worse.
One way to triangulate the patients’ self report of pain reduction is 
with two test items from FIQ – the single-scale pain assessment and 
the single-scale tiredness reduction assessment. On the FIQ pain scale, 
the median pain level was 9 before treatment and 2 after treatment 
(P<0.0001; WSR). The FIQ tiredness scale showed a reduction from 
10 before treatment to 2 after treatment (P<0.0001; WSR).
Because FM is known to cause stiffness, and pain decreases length 
of time individuals can stand or sit, sitting, standing and ROM tests 
were used. Table 5 reports the results of the physical assessments before 
and after treatment. The length of time patients can sit increased sig-
nificantly (P<0.0001), as did the length of time standing (P<0.0001). 
These results are presented in Figures 3 and 4.
Table 5 presents the changes in cervical ROM and cervical tone 
before and after treatment. Figure 5 shows that most patients (11 of 
19) had 25% ROM and none had full ROM at baseline, while nine of 
19 patients had >75% ROM and only three of 19 had <25% ROM 
after treatment. Similarly, Figure 6 shows that 13 of 19 patients were 
more hypertonic and none had normal tone at baseline, while there 
were seven patients with normal tone, six who were hypertonic and 
none who were more hypertonic after treatment. 
The median cervical muscle ROM increased from a baseline of 25% 
to 75% following treatment (P=0.001; WSR), while muscle tone 
changed from hypertonic at baseline to normal tone (P=0.0002; WSR). 
With highly significant reductions in pain and impact of FM on qual-
ity of life, it is important to observe the return of FM symptoms following 
Figure 3) Length of time sitting before and after treatment
Figure 4) Length of time standing before and after treatment
TablE 4
Self-report following treatment
Range
Minimum Maximum
Medication intake, n (%)    
   Reduced dosage 14 (73.68)   
   Stopped totally 5 (26.32)   
Subjective improvement, %,  
median (q1, q3)
   
   Pain 70 (50, 80) 35 90
   Mood 65 (45, 85) 35 100
   Insomnia 65 (40, 85) 30 95
   Activities of daily living 70 (50, 80) 35 90
Global impression of change, n (%)    
   Negative 0 (0)   
   Slightly better 2 (10.53)   
   Much better 8 (42.11)   
   Very much better 9 (47.37)
q Quartile
Figure 2) Jenkins Sleep Scale (JSS) before and after comparison
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the end of treatment. Table 6 presents results of symptom recurrence. 
Although three patients (15.8%) reported no recurrence of symptoms 
within 14 days, 84.2% experienced a recurrence of pain (68.4%) or sleep 
disturbance (17.8%). For patients with recurring pain, the pain recurred 
within a mean of eight days (minimum seven days, maximum 14 days). 
For patients with recurring insomnia, the symptom recurred within a 
mean of 10 days (minimum seven days, maximum 14 days).
coNcLusioN 
The results of the present study suggest that LFSS may be beneficial in 
the treatment of FM. It is important to note that the present study was 
an open-label investigation, with no group or baseline control. The 
contribution to quality of life appears to be highly significant and the 
reduction in medication important. The mechanisms by which the 
effects were obtained in the present study cannot be definitely identi-
fied, but highlight the need for further exploration of the effect of 
LFSS on muscular and joint mobility through cellular stimulation and 
the need for brain imaging to determine the effect of LFSS on possible 
neural dysrhythmias that may underlie FM. Because personal-choice 
music listening has been shown to have an effect on pain, further 
research should explore variants of the treatment used including the 
combination of LFSS with music listening and the use of auditory 
isochronous 40 Hz sound as an alternative or adjunct to LFSS. 
Furthermore, it must be noted that the present analysis was a pilot 
study that had limitations as an open-label study without an initial 
baseline, with limited follow-up and with no comparison group. 
However, the results are strong enough to warrant further research and 
exploration of continued dosing effects. 
AckNoWLedgeMeNTs: The authors gratefully acknowledge the 
assistance of Chang Ye in the statistical analysis of the data. 
FuNdiNg: Conrad Institute for Music Therapy Research, Wilfrid 
Laurier University, Waterloo, Ontario.
Figure 5) Range of motion (ROM) before and after treatment Figure 6) Muscle tone before and after treatment
TablE 5
Physical ability results
Test Median Mean ± SD
Range
Signed rank PMinimum Maximum
Sitting, min
   Initial 10.0 17.37±12.84 5 60
   Final 30.0 52.63±37.61 20 180
   Difference 20.0 35.26 95 <0.0001
Standing, min
   Initial 10.0 16.32±9.10 5 30
   Final 25.9 55.26±41.07 20 180
   Difference 15.0 38.95 95 <0.0001
Range of motion*
   Initial 1.0 1.16±0.76 0.0 3.0
   Final 3.0 2.77±1.17 1.0 4.0
   Difference 2.0 1.54 33 0.001
Cervical muscle tone†
   Initial 2.0 1.68±0.48 1.0 2.0
   Final 0.0 0.46±0.52 0.0 1.0
   Difference 2.0 1.31 −45.5 0.0002
*Range of motion (ROM) scores: 0 = no ROM; 1 = 25% ROM; 2 = 50% ROM; 3 = 75% ROM; 4 = 100% ROM; †Muscle tone: 0 = normal tone; 1 = hypertonic; 
2 = more hypertonic
TablE 6
Recurrence of symptoms following treatment
First recurrence of 
symptoms (total n=19) q1, q3
Range
Minimum Maximum
Pain, n (%) 13 (68.4) 
   Time to recurrence, days 8 7, 10 7 14
Insomnia, n (%) 3 (15.8)
   Time to recurrence, days 10 7, 11 7 11
None, n (%) 3 (15.8)
q Quartile
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